Loading...
XSHE
300238
Market cap549mUSD
Dec 05, Last price  
14.64CNY
1D
0.14%
1Q
-11.11%
Jan 2017
-56.10%
IPO
44.88%
Name

Guanhao Biotech Co Ltd

Chart & Performance

D1W1MN
XSHE:300238 chart
P/E
141.59
P/S
10.28
EPS
0.10
Div Yield, %
Shrs. gr., 5y
0.67%
Rev. gr., 5y
-2.93%
Revenues
377m
-6.60%
22,375,47935,192,06065,569,016102,618,066128,510,115147,020,069168,501,935190,356,664226,172,526312,789,660450,366,981458,461,849437,886,453436,957,168488,981,886377,285,014404,178,697377,483,103
Net income
27m
-11.57%
2,810,2427,094,82214,416,92132,341,05940,422,52037,031,45140,573,89450,103,14763,366,04256,955,82057,475,20445,746,533046,594,90073,687,006031,005,79827,416,909
CFO
50m
-8.49%
04,802,7825,551,30333,755,38335,453,97949,124,92041,487,99565,448,67167,865,96230,680,82119,218,21532,276,11692,545,564103,839,533122,394,24370,983,73054,149,82749,554,796
Dividend
Jun 20, 20180.05 CNY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Guanhao Biotech Co.,Ltd. develops, manufactures, and markets regenerative medicine in China. It offers NormalGEN, a type of biological dura repair patch manufactured from animal tissue; GrandNeuro, an artificial dura patch for dura repairing; ThormalGEN, a biological surgical patch manufactured from animal tissue for surgical repairs; DermalGEN, a wound dressing product manufactured from animal tissue for use on burns, scalds, and wounds due to skin loss or trauma; and IREAL breast patch. The company was founded in 1999 and is based in Guangzhou, China.
IPO date
Jul 06, 2011
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT